retatrutide clinical trial duration Half-Life & Pharmacokinetics: 6-Day Decay Curve When does the first phase

We always have a way to meet and exceed our customers expectations

The ESSENCE trial 240-week readout in 2028 will be a landmark, but longer follow-up and adequately powered studies in higher-risk populations (F3-F4 fibrosis) remain priorities

Minis E, Stanford FC, Mahalingaiah S

It is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) due to risks observed in animal studies (47)

doi: 10.1111/dom.13979 68 FurihataKMimuraHUrvaSOuraTOhwakiKImaokaT

Retatrutide is an investigational compound, and the FDA has not approved it for any indication